Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

Exclusion Criteria

• •Not willing to remain at Roswell Park Cancer Institute (RPCI), and in follow up, as required
• •Presence of medical conditions which, in the opinion of the investigator, would place either the participant or the integrity of the data at risk
• •Serum creatinine \> ULN, SGOT or SGPT \>= 2.0 x ULN, or bilirubin \> ULN
• •Treatment with an investigational drug within 30 days prior to the dose of study drug
• •Use of selenium \[Se\] supplements greater than the 100 mcg dose common in multivitamins between 30 days before study drug initiation and Day 84
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent (e.g., reaction to other Se supplements)
• •Participants who have donated 1 unit of blood within 30 days prior to the first dose of investigational agent
• •Eastern Cooperative Oncology Group (ECOG) performance status \> 1
• •Diagnosed with cancer, other than non-melanoma skin cancer, in last 2 years
• •Under treatment for any cancer
• •Use of glucose-lowering agents or a condition that would make a fast from 10:00 pm the evening before until 11:00 am on days 1 and 84 hazardous
• •American Urological Association (AUA) total symptom score \> 10 or any individual symptom score of greater than or equal to 4
• •Psychiatric illness which would prevent compliance with the intervention or would prevent the patient from providing informed consent
• •Medical conditions which in the opinion of the treating physician would make this protocol unreasonably hazardous for the participant